{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:06:38Z","timestamp":1793232398034,"version":"4.5.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,3,31]],"date-time":"2018-03-31T00:00:00Z","timestamp":1522454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s40121-018-0198-x","type":"journal-article","created":{"date-parts":[[2018,3,31]],"date-time":"2018-03-31T02:30:01Z","timestamp":1522463401000},"page":"197-217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties"],"prefix":"10.1007","volume":"7","author":[{"given":"Sarah C. J.","family":"Jorgensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Mercuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Rybak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,31]]},"reference":[{"key":"198_CR1","unstructured":"US Food and Drug Administration. IMS Health Vector One, National Total Patient Tracker. Extracted July 2012."},{"key":"198_CR2","unstructured":"US Food and Drug Administration. ICHARUS. Extracted July 2012."},{"issue":"6","key":"198_CR3","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1592\/phco.29.6.736","volume":"29","author":"A Wong-Beringer","year":"2009","unstructured":"Wong-Beringer A, Nguyen LH, Lee M, Shriner KA, Pallares J. An antimicrobial stewardship program with a focus on reducing fluoroquinolone overuse. Pharmacotherapy. 2009;29(6):736\u201343.","journal-title":"Pharmacotherapy."},{"issue":"7","key":"198_CR4","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1001\/jama.289.7.885","volume":"289","author":"MM Neuhauser","year":"2003","unstructured":"Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA. 2003;289(7):885\u20138.","journal-title":"JAMA"},{"issue":"4","key":"198_CR5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1556\/AMicr.61.2014.002","volume":"61","author":"M Fuzi","year":"2014","unstructured":"Fuzi M. Has the use of fluoroquinolones facilitated the widespread dissemination of methicillin-resistant Staphylococcus aureus and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in the healthcare setting? Acta Microbiol Immunol Hung. 2014;61(4):399\u2013405.","journal-title":"Acta Microbiol Immunol Hung"},{"key":"198_CR6","unstructured":"BAXDELA (delafloxacin) product package insert. Lincolnshire: Melinta Therapeutics, Inc. 2017."},{"issue":"2","key":"198_CR7","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1128\/AAC.01201-10","volume":"55","author":"S Lemaire","year":"2011","unstructured":"Lemaire S, Tulkens PM, Van Bambeke F. Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus. Antimicrob Agents Chemother. 2011;55(2):649\u201358.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"198_CR8","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1093\/jac\/dks307","volume":"67","author":"JM Remy","year":"2012","unstructured":"Remy JM, Tow-Keogh CA, McConnell TS, Dalton JM, Devito JA. Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization. J Antimicrob Chemother. 2012;67(12):2814\u201320.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 2","key":"198_CR9","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1086\/314056","volume":"31","author":"DC Hooper","year":"2000","unstructured":"Hooper DC. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis. 2000;31(Suppl 2):S24\u20138.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"198_CR10","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1093\/jac\/dkf047","volume":"49","author":"HJ Smith","year":"2002","unstructured":"Smith HJ, Nichol KA, Hoban DJ, Zhanel GG. Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims. J Antimicrob Chemother. 2002;49(6):893\u20135.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"198_CR11","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1128\/AAC.47.10.3260-3269.2003","volume":"47","author":"AM Nilius","year":"2003","unstructured":"Nilius AM, Shen LL, Hensey-Rudloff D, Almer LS, Beyer JM, Balli DJ, et al. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob Agents Chemother. 2003;47(10):3260\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"198_CR12","unstructured":"Duffy M, DeVito JA, Remy J, Burbak ES. Delafloxacin chemical properties lead to increased potency against gram-positive pathogens, including quinolone-resistant pathogens II. In: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12\u201315, 2010, Boston, MA, Abstract E-182."},{"issue":"10","key":"198_CR13","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1128\/AAC.45.10.2703-2709.2001","volume":"45","author":"T Lu","year":"2001","unstructured":"Lu T, Zhao X, Li X, Drlica-Wagner A, Wang JY, Domagala J, et al. Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus. Antimicrob Agents Chemother. 2001;45(10):2703\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"198_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1093\/jac\/dkn136","volume":"62","author":"R Okumura","year":"2008","unstructured":"Okumura R, Hirata T, Onodera Y, Hoshino K, Otani T, Yamamoto T. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 2008;62(1):98\u2013104.","journal-title":"J Antimicrob Chemother"},{"key":"198_CR15","unstructured":"Burbak ES, DeVito JA, Remy J, Duffy ME. Delafloxacin chemical properties lead to increased potency against gram-positive pathogens, including quinolone-resistant pathogens I. In: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12\u201315, 2010, Boston, MA, Abstract E-182."},{"key":"198_CR16","volume-title":"Performance standards for antimicrobial susceptibility testing 27th informational supplement. CLSI document M100-S27","author":"Clinical and Laboratory Standards Institute","year":"2017","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing 27th informational supplement. CLSI document M100-S27. Wayne: CLSI; 2017."},{"issue":"12","key":"198_CR17","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.3201\/eid0912.030168","volume":"9","author":"DF Sahm","year":"2003","unstructured":"Sahm DF, Thornsberry C, Jones ME, Karlowsky JA. Factors influencing fluoroquinolone resistance. Emerg Infect Dis. 2003;9(12):1651\u20134.","journal-title":"Emerg Infect Dis"},{"key":"198_CR18","doi-asserted-by":"publisher","unstructured":"McCurdy S, Lawrence L, Quintas M, Woosley L, Flamm R, Tseng C, et al. In vitro activity of delafloxacin and microbiological response against fluoroquinolone-susceptible and nonsusceptible staphylococcus aureus isolates from two phase 3 studies of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2017;61(9). \n                    https:\/\/doi.org\/10.1128\/AAC.00772-17\n                    \n                  .","DOI":"10.1128\/AAC.00772-17"},{"key":"198_CR19","doi-asserted-by":"publisher","unstructured":"Pfaller MA, Sader HS, Rhomberg PR, Flamm RK. In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014. Antimicrob Agents Chemother. 2017;61(4). \n                    https:\/\/doi.org\/10.1128\/AAC.02609-16\n                    \n                  .","DOI":"10.1128\/AAC.02609-16"},{"key":"198_CR20","unstructured":"Sheikh J. Clinical microbiology review. Delafloxacin. NDA#208610, 208611. Melinta Therapeutics, Inc. Division of Anti-Infective Products. Center for Drug Evaluation and Research. US Food and Drug Administration; 2017."},{"issue":"6","key":"198_CR21","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1128\/AAC.47.6.1867-1874.2003","volume":"47","author":"GG Zhanel","year":"2003","unstructured":"Zhanel GG, Palatnick L, Nichol KA, Bellyou T, Low DE, Hoban DJ. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother. 2003;47(6):1867\u201374.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"198_CR22","doi-asserted-by":"publisher","first-page":"6381","DOI":"10.1128\/AAC.00941-16","volume":"60","author":"RK Flamm","year":"2016","unstructured":"Flamm RK, Rhomberg PR, Huband MD, Farrell DJ. In vitro activity of delafloxacin tested against isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother. 2016;60(10):6381\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"198_CR23","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1128\/AAC.48.7.2771-2777.2004","volume":"48","author":"LS Almer","year":"2004","unstructured":"Almer LS, Hoffrage JB, Keller EL, Flamm RK, Shortridge VD. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against gram-positive and gram-negative organisms. Antimicrob Agents Chemother. 2004;48(7):2771\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"198_CR24","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1128\/AAC.02798-15","volume":"60","author":"OO Soge","year":"2016","unstructured":"Soge OO, Salipante SJ, No D, Duffy E, Roberts MC. In vitro activity of delafloxacin against clinical Neisseria gonorrhoeae isolates and selection of gonococcal delafloxacin resistance. Antimicrob Agents Chemother. 2016;60(5):3106\u201311.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"198_CR25","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/00007435-199811000-00002","volume":"25","author":"JW Tapsall","year":"1998","unstructured":"Tapsall JW, Shultz TR, Limnios EA, Donovan B, Lum G, Mulhall BP. Failure of azithromycin therapy in gonorrhea and discorrelation with laboratory test parameters. Sex Transm Dis. 1998;25(10):505\u20138.","journal-title":"Sex Transm Dis"},{"key":"198_CR26","unstructured":"Melinta Therapeutics. Melinta therapeutics ceases phases 3 proceeding study. Press release. \n                    http:\/\/melinta.com\/melinta-therapeutics-ceases-phase-3-proceeding-study\/\n                    \n                  . Accessed 20 Dec 2017."},{"issue":"2","key":"198_CR27","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1128\/AAC.44.2.283-286.2000","volume":"44","author":"H Tomioka","year":"2000","unstructured":"Tomioka H, Sato K, Kajitani H, Akaki T, Shishido S. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother. 2000;44(2):283\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"198_CR28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1179\/joc.2004.16.3.227","volume":"16","author":"E Sillerstrom","year":"2004","unstructured":"Sillerstrom E, Wahlund E, Nord CE. In vitro activity of ABT-492 against anaerobic bacteria. J Chemother. 2004;16(3):227\u20139.","journal-title":"J Chemother"},{"issue":"2","key":"198_CR29","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/jac\/dkg320","volume":"52","author":"Y Golan","year":"2003","unstructured":"Golan Y, McDermott LA, Jacobus NV, Goldstein EJ, Finegold S, Harrell LJ, et al. Emergence of fluoroquinolone resistance among Bacteroides species. J Antimicrob Chemother. 2003;52(2):208\u201313.","journal-title":"J Antimicrob Chemother"},{"key":"198_CR30","unstructured":"Vernon J, Freeman J, Wilcox MH. Susceptibility of common Clostridium difficile PCR ribotypes to delafloxacin and seven comparator antimicrobials. In: 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17\u201321, 2015. San Diego, CA, Abstract 2408."},{"issue":"1","key":"198_CR31","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.clinthera.2015.11.019","volume":"38","author":"R Hoover","year":"2016","unstructured":"Hoover R, Hunt T, Benedict M, Paulson SK, Lawrence L, Cammarata S, et al. Safety, tolerability, and pharmacokinetic properties of intravenous delafloxacin after single and multiple doses in healthy volunteers. Clin Ther. 2016;38(1):53\u201365.","journal-title":"Clin Ther"},{"issue":"1","key":"198_CR32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.clinthera.2015.10.016","volume":"38","author":"R Hoover","year":"2016","unstructured":"Hoover R, Hunt T, Benedict M, Paulson SK, Lawrence L, Cammarata S, et al. Single and multiple ascending-dose studies of oral delafloxacin: effects of food, sex, and age. Clin Ther. 2016;38(1):39\u201352.","journal-title":"Clin Ther"},{"key":"198_CR33","unstructured":"Wu K, Yan Z. Clinical pharmacology and biopharmaceutical review. Delafloxacin. NDA#208610, 208611. Melinta Therapeutics, Inc. Division of Anti-Infective Products. Center for Drug Evaluation and Research. US Food and Drug Administration; 2017."},{"key":"198_CR34","unstructured":"CIPRO (ciprofloxacin) product package insert. Whippany: Bayer Corp.; 2017."},{"key":"198_CR35","unstructured":"AVELOX (moxifloxacin) product package insert. Kenilworth: Merck Co.; 2017."},{"issue":"5","key":"198_CR36","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ijantimicag.2016.08.012","volume":"48","author":"AK Thabit","year":"2016","unstructured":"Thabit AK, Crandon JL, Nicolau DP. Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens. Int J Antimicrob Agents. 2016;48(5):535\u201341.","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"198_CR37","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3109\/00498254.2015.1042946","volume":"45","author":"A McEwen","year":"2015","unstructured":"McEwen A, Lawrence L, Hoover R, Stevens L, Mair S, Ford G, et al. Disposition, metabolism and mass balance of delafloxacin in healthy human volunteers following intravenous administration. Xenobiotica. 2015;45(12):1054\u201362.","journal-title":"Xenobiotica"},{"issue":"5","key":"198_CR38","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/jac\/46.5.669","volume":"46","author":"DH Wright","year":"2000","unstructured":"Wright DH, Brown GH, Peterson ML, Rotschafer JC. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother. 2000;46(5):669\u201383.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"198_CR39","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.1128\/AAC.00647-16","volume":"60","author":"AJ Lepak","year":"2016","unstructured":"Lepak AJ, Andes DR. In vivo pharmacodynamic target assessment of delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a murine lung infection model. Antimicrob Agents Chemother. 2016;60(8):4764\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"198_CR40","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/joim.12004","volume":"272","author":"U Romling","year":"2012","unstructured":"Romling U, Balsalobre C. Biofilm infections, their resilience to therapy and innovative treatment strategies. J Intern Med. 2012;272(6):541\u201361.","journal-title":"J Intern Med"},{"issue":"6","key":"198_CR41","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1128\/AAC.00181-13","volume":"57","author":"J Bauer","year":"2013","unstructured":"Bauer J, Siala W, Tulkens PM, Van Bambeke F. A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms. Antimicrob Agents Chemother. 2013;57(6):2726\u201337.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"198_CR42","doi-asserted-by":"publisher","first-page":"6385","DOI":"10.1128\/AAC.03482-14","volume":"58","author":"W Siala","year":"2014","unstructured":"Siala W, Mingeot-Leclercq MP, Tulkens PM, Hallin M, Denis O, Van Bambeke F. Comparison of the antibiotic activities of daptomycin, vancomycin, and the investigational fluoroquinolone delafloxacin against biofilms from Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother. 2014;58(11):6385\u201397.","journal-title":"Antimicrob Agents Chemother"},{"key":"198_CR43","unstructured":"Ding Y, Villet RA, Lee JC, Hooper DC. Treatment of renal abscesses caused by Staphylococcus aureus MW2, using delafloxacin and moxifloxacin. In: 21th European Congress of Clinical Microbiology and Infectious Diseases, May 7\u201310, 2011. Milan, Italy, Abstract 1506."},{"issue":"2","key":"198_CR44","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.juro.2015.01.094","volume":"194","author":"W So","year":"2015","unstructured":"So W, Crandon JL, Nicolau DP. Effects of urine matrix and pH on the potency of delafloxacin and ciprofloxacin against urogenic Escherichia coli and Klebsiella pneumoniae. J Urol. 2015;194(2):563\u201370.","journal-title":"J Urol"},{"issue":"3","key":"198_CR45","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1155\/2012\/569093","volume":"23","author":"PJ Baudry-Simner","year":"2012","unstructured":"Baudry-Simner PJ, Singh A, Karlowsky JA, Hoban DJ, Zhanel GG, Canadian Antimicrobial Resistance A. Mechanisms of reduced susceptibility to ciprofloxacin in Escherichia coli isolates from Canadian hospitals. Can J Infect Dis Med Microbiol. 2012;23(3):e60\u20134.","journal-title":"Can J Infect Dis Med Microbiol."},{"issue":"1","key":"198_CR46","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/jac\/dkh242","volume":"54","author":"AA Firsov","year":"2004","unstructured":"Firsov AA, Vostrov SN, Lubenko IY, Arzamastsev AP, Portnoy YA, Zinner SH. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model. J Antimicrob Chemother. 2004;54(1):178\u201386.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"198_CR47","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/jac\/dkv411","volume":"71","author":"J Kingsley","year":"2016","unstructured":"Kingsley J, Mehra P, Lawrence LE, Henry E, Duffy E, Cammarata SK, et al. A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin. J Antimicrob Chemother. 2016;71(3):821\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"198_CR48","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ijid.2014.10.009","volume":"30","author":"W O\u2019Riordan","year":"2015","unstructured":"O\u2019Riordan W, Mehra P, Manos P, Kingsley J, Lawrence L, Cammarata S. A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections. Int J Infect Dis. 2015;30:67\u201373.","journal-title":"Int J Infect Dis."},{"key":"198_CR49","unstructured":"Longcor J, Hopkins S, Wikler M, Lawrence L. A phase 2 safety and efficacy study of oral delafloxacin (DLX) in subjects with acute bacterial exacerbation of chronic bronchitis (ABECB). IDWeek, October 17\u201321, 2012, San Diego, CA, Abstract 1071."},{"key":"198_CR50","unstructured":"Longcor J, Hopkins S, Wikler M, Lawrence L. A phase 2 safety and efficacy study of oral delafloxacin (DLX) in community acquired pneumonia (CAP). IDWeek, October 17\u201321, 2012, SanDiego, CA, Abstract 1069."},{"key":"198_CR51","unstructured":"Charles JK. Statistical review. Delafloxacin. NDA#208610, 208611. Melinta Therapeutics, Inc. Division of Anti-Infective Products. Center for Drug Evaluation and Research. US Food and Drug Administration; 2017."},{"issue":"12","key":"198_CR52","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.1093\/jac\/dkx329","volume":"72","author":"J Pullman","year":"2017","unstructured":"Pullman J, Gardovskis J, Farley B, Sun E, Quintas M, Lawrence L, et al. Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a phase 3, double-blind, randomized study. J Antimicrob Chemother. 2017;72(12):3471\u201380.","journal-title":"J Antimicrob Chemother."},{"issue":"Suppl 1","key":"198_CR53","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1086\/319379","volume":"32","author":"LA Mandell","year":"2001","unstructured":"Mandell LA, Ball P, Tillotson G. Antimicrobial safety and tolerability: differences and dilemmas. Clin Infect Dis. 2001;32(Suppl 1):S72\u20139.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"198_CR54","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1345\/aph.1K347","volume":"41","author":"AJ Mehlhorn","year":"2007","unstructured":"Mehlhorn AJ, Brown DA. Safety concerns with fluoroquinolones. Ann Pharmacother. 2007;41(11):1859\u201366.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"198_CR55","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/S1473-3099(16)00051-7","volume":"16","author":"GS Tillotson","year":"2016","unstructured":"Tillotson GS. FDA and the safe and appropriate antibiotic use of fluoroquinolones. Lancet Infect Dis. 2016;16(3):e11\u20132.","journal-title":"Lancet Infect Dis."},{"key":"198_CR56","unstructured":"Jjingo CJ. Clinical review. Delafloxacin. NDA#208610, 208611. Melinta Therapeutics, Inc. Division of Anti-Infective Products. Center for Drug Evaluation and Research. US Food and Drug Administration; 2017."},{"issue":"11","key":"198_CR57","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1128\/AAC.41.11.2389","volume":"41","author":"Y Kashida","year":"1997","unstructured":"Kashida Y, Kato M. Characterization of fluoroquinolone-induced Achilles tendon toxicity in rats: comparison of toxicities of 10 fluoroquinolones and effects of anti-inflammatory compounds. Antimicrob Agents Chemother. 1997;41(11):2389\u201393.","journal-title":"Antimicrob Agents Chemother"},{"key":"198_CR58","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2147\/DDDT.S106071","volume":"11","author":"FJ Candel","year":"2017","unstructured":"Candel FJ, Penuelas M. Delafloxacin: design, development and potential place in therapy. Drug Des Dev Ther. 2017;11:881\u201391.","journal-title":"Drug Des Dev Ther."},{"issue":"Suppl 2","key":"198_CR59","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.1086\/428055","volume":"41","author":"RC Owens Jr","year":"2005","unstructured":"Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis. 2005;41(Suppl 2):S144\u201357.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"198_CR60","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1592\/phco.21.1.35.34440","volume":"21","author":"DN Fish","year":"2001","unstructured":"Fish DN, North DS. Gatifloxacin, an advanced 8-methoxy fluoroquinolone. Pharmacotherapy. 2001;21(1):35\u201359.","journal-title":"Pharmacotherapy."},{"issue":"6","key":"198_CR61","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1128\/AAC.04813-14","volume":"59","author":"JS Litwin","year":"2015","unstructured":"Litwin JS, Benedict MS, Thorn MD, Lawrence LE, Cammarata SK, Sun E. A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization. Antimicrob Agents Chemother. 2015;59(6):3469\u201373.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"198_CR62","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1086\/496986","volume":"41","author":"J Pepin","year":"2005","unstructured":"Pepin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41(9):1254\u201360.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"198_CR63","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1002\/jps.22109","volume":"99","author":"DR Luke","year":"2010","unstructured":"Luke DR, Tomaszewski K, Damle B, Schlamm HT. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). J Pharm Sci. 2010;99(8):3291\u2013301.","journal-title":"J Pharm Sci"},{"issue":"6","key":"198_CR64","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1086\/655827","volume":"51","author":"GR Corey","year":"2010","unstructured":"Corey GR, Wilcox M, Talbot GH, Friedland HD, Baculik T, Witherell GW, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010;51(6):641\u201350.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"198_CR65","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/S1473-3099(14)70737-6","volume":"14","author":"GJ Moran","year":"2014","unstructured":"Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P. Tedizolid for 6\u00a0days versus linezolid for 10\u00a0days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014;14(8):696\u2013705.","journal-title":"Lancet Infect Dis."},{"issue":"23","key":"198_CR66","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","volume":"370","author":"GR Corey","year":"2014","unstructured":"Corey GR, Kabler H, Mehra P, Gupta S, Overcash JS, Porwal A, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med. 2014;370(23):2180\u201390.","journal-title":"N Engl J Med"},{"issue":"23","key":"198_CR67","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","volume":"370","author":"HW Boucher","year":"2014","unstructured":"Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169\u201379.","journal-title":"N Engl J Med"},{"issue":"9","key":"198_CR68","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3201\/eid1209.060397","volume":"12","author":"L LeBlanc","year":"2006","unstructured":"LeBlanc L, Pepin J, Toulouse K, Ouellette MF, Coulombe MA, Corriveau MP, et al. Fluoroquinolones and risk for methicillin-resistant Staphylococcus aureus, Canada. Emerg Infect Dis. 2006;12(9):1398\u2013405.","journal-title":"Emerg Infect Dis."},{"issue":"1","key":"198_CR69","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1365-2125.2011.04161.x","volume":"74","author":"MA Aldeyab","year":"2012","unstructured":"Aldeyab MA, Harbarth S, Vernaz N, Kearney MP, Scott MG, Darwish Elhajji FW, et al. The impact of antibiotic use on the incidence and resistance pattern of extended-spectrum beta-lactamase-producing bacteria in primary and secondary healthcare settings. Br J Clin Pharmacol. 2012;74(1):171\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 4","key":"198_CR70","doi-asserted-by":"publisher","first-page":"S341","DOI":"10.1086\/382690","volume":"38","author":"DL Paterson","year":"2004","unstructured":"Paterson DL. \u201cCollateral damage\u201d from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis. 2004;38(Suppl 4):S341\u20135.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"198_CR71","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/cid\/cir034","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285\u201392.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"198_CR72","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1093\/cid\/ciq257","volume":"52","author":"K Gupta","year":"2011","unstructured":"Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103\u201320.","journal-title":"Clin Infect Dis"},{"key":"198_CR73","unstructured":"Centers for Disease Control and Prevention. Antibiotic-resistant Gonorrhea. December 6, 2017. \n                    https:\/\/www.cdc.gov\/std\/gonorrhea\/arg\/\n                    \n                  . Accessed 5 Feb 2018."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-018-0198-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40121-018-0198-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-018-0198-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,30]],"date-time":"2019-03-30T20:19:09Z","timestamp":1553977149000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40121-018-0198-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,31]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["198"],"URL":"https:\/\/doi.org\/10.1007\/s40121-018-0198-x","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,31]]},"assertion":[{"value":"20 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}